Literature DB >> 26981446

Matrix metalloproteinase-2 as a superior biomarker for peritoneal deterioration in peritoneal dialysis.

Ichiro Hirahara1, Eiji Kusano1, Yoshiyuki Morishita1, Makoto Inoue1, Tetsu Akimoto1, Osamu Saito1, Shigeaki Muto1, Daisuke Nagata1.   

Abstract

AIM: To investigate the efficacy of effluent biomarkers for peritoneal deterioration with functional decline in peritoneal dialysis (PD).
METHODS: From January 2005 to March 2013, the subjects included 218 PD patients with end-stage renal disease at 18 centers. Matrix metalloproteinase-2 (MMP-2), interleukin-6 (IL-6), hyaluronan, and cancer antigen 125 (CA125) in peritoneal effluent were quantified with enzyme-linked immunosorbent assay. Peritoneal solute transport rate was assessed by peritoneal equilibration test (PET) to estimate peritoneal deterioration.
RESULTS: The ratio of the effluent level of creatinine (Cr) obtained 4 h after injection (D) to that of plasma was correlated with the effluent levels of MMP-2 (ρ = 0.74, P < 0.001), IL-6 (ρ = 0.46, P < 0.001), and hyaluronan (ρ = 0.27, P < 0.001), but not CA125 (ρ = 0.13, P = 0.051). The area under receiver operating characteristic curve for the effluent levels of MMP-2, IL-6, and hyaluronan against high PET category were 0.90, 0.78, 0.62, and 0.51, respectively. No patient developed new-onset encapsulating peritoneal sclerosis for at least 1.5 years after peritoneal effluent sampling.
CONCLUSION: The effluent MMP-2 level most closely reflected peritoneal solute transport rate. MMP-2 can be a reliable indicator of peritoneal deterioration with functional decline.

Entities:  

Keywords:  Encapsulating peritoneal sclerosis; Matrix metalloproteinase-2; Peritoneal deterioration; Peritoneal dialysis; Peritoneal solute transport

Year:  2016        PMID: 26981446      PMCID: PMC4777793          DOI: 10.5527/wjn.v5.i2.204

Source DB:  PubMed          Journal:  World J Nephrol        ISSN: 2220-6124


  23 in total

1.  High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment.

Authors:  Ryo Yamamoto; Masaaki Nakayama; Toshio Hasegawa; Numata Miwako; Hiroyasu Yamamoto; Keitaro Yokoyami; Masato Ikeda; Naohiko Kato; Hiroshi Hayakawa; Hajime Takahashi; Yasushi Otsuka; Yoshindo Kawaguchi; Tastuo Hosoya
Journal:  Adv Perit Dial       Date:  2002

Review 2.  Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures.

Authors:  Yoshindo Kawaguchi; Akira Saito; Hideki Kawanishi; Masaaki Nakayama; Masanobu Miyazaki; Hidetomo Nakamoto; Anders Tranaeus
Journal:  Perit Dial Int       Date:  2005-04       Impact factor: 1.756

3.  Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?

Authors:  R T Krediet
Journal:  Perit Dial Int       Date:  2013 Nov-Dec       Impact factor: 1.756

4.  Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD.

Authors:  Edwina A Brown; Wim Van Biesen; Fredric O Finkelstein; Helen Hurst; David W Johnson; Hideki Kawanishi; Roberto Pecoits-Filho; Graham Woodrow
Journal:  Perit Dial Int       Date:  2009 Nov-Dec       Impact factor: 1.756

5.  Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane Dysfunction.

Authors:  Yeoungjee Cho; David W Johnson; David A Vesey; Carmel M Hawley; Elaine M Pascoe; Margaret Clarke; Nicholas Topley
Journal:  Perit Dial Int       Date:  2014-10-07       Impact factor: 1.756

6.  Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis.

Authors:  Deirisa Lopes Barreto; Dirk G Struijk; Raymond T Krediet
Journal:  Am J Kidney Dis       Date:  2014-12-17       Impact factor: 8.860

7.  Dialysate cytokine levels do not predict encapsulating peritoneal sclerosis.

Authors:  Catriona Goodlad; Frederick W K Tam; Sohail Ahmad; Gurjeet Bhangal; Bernard V North; Edwina A Brown
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

8.  Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients.

Authors:  V C Gandhi; H M Humayun; T S Ing; J T Daugirdas; V R Jablokow; S Iwatsuki; W P Geis; J E Hano
Journal:  Arch Intern Med       Date:  1980-09

9.  Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats.

Authors:  Ichiro Hirahara; Yoshitaka Ishibashi; Shinya Kaname; Eiji Kusano; Toshiro Fujita
Journal:  Nephrol Dial Transplant       Date:  2008-09-12       Impact factor: 5.992

Review 10.  Dialysate cancer antigen 125 in long-term peritoneal dialysis patients.

Authors:  Panida Ditsawanon; Ouppatham Supasyndh; Pornanong Aramwit
Journal:  Clin Exp Nephrol       Date:  2013-06-12       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.